智通财经APP讯，兆科眼科-B(06622)公布，该公司与AFT Pharmaceuticals Limited(AFT，一间以新西兰为基地的领先健康护理产品制造商及分销商)就BRIMOCHOL™PF订立分销及供应协议。
BRIMOCHOL™PF乃一种用于矫正因老花眼而丧失近距离视力的潜在疗法。该公司已就BRIMOCHOL™PF与Tenpoint Therapeutics Ltd.(Tenpoint，通过Tenpoint Therapeutics Ltd.与Visus Therapeutics,Inc.合并成立)建立伙伴关系。Tenpoint为一间全球性临床阶段生物技术公司，开发突破性的疗法，以恢复老化眼睛的视力。
Tenpoint Therapeutics最近公布了BRIO-II的积极顶线结果。BRIO-II为该公司的第二个第三期关键试验。在该研究中，BRIMOCHOL™PF成功达到美国及欧盟╱英国预定的视力主要研究终点，在8小时近距离视力方面具有重大统计显著性改善，为2025年上半年在美国提交新药申请铺平道路。
根据协议条款，兆科眼科有权授予AFT于澳洲及新西兰进口、分销、推广、营销及销售BRIMOCHOL™PF的独家权利。作为协议的一部分，AFT将代表该公司取得相关的当地药物注册。该公司将收取一笔不可退还及不可抵扣的预付款，并可按照若干成就获得额外的里程碑付款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.